Tiziana Life Sciences announced the last patient has completed their final visit in the Phase 2a INFORM-MS trial testing intranasal foralumab for non-active secondary progressive multiple sclerosis (na-SPMS). The trial involved 48 patients across multiple U.S. sites and evaluated safety, tolerability, and efficacy over 12 weeks. Topline data is expected in October, with an open-label extension allowing all participants to receive the drug for longer-term safety and efficacy data. This milestone advances development of a potential treatment for a condition with unmet medical needs.
Tiziana Life Sciences' recent milestone in its Phase 2a MS drug trial is offered here with Pluang's Health sector data for context. As of Sep 21, 2026 20:01 WIB, 56 of 95 priced Health-sector US stocks on Pluang rose while 25 fell. Notable movers include Inovio Pharmaceuticals Inc at USD 1.26 with a 1-day change of +1.61%, Canopy Growth Corp at USD 0.92 down 1.54%, and Ginkgo Bioworks Holdings Inc at USD 8.00 up 1.52%.
Alkermes plc's drug ALKS7290 demonstrated significant improvement in ADHD symptoms in a Phase 1b trial, with patients showing a 14- to 19-point gain on a 54-point scale within two weeks. This outperforms typical placebo effects, which range from 6 to...
Morgan Stanley upgraded NNN REIT from Neutral to Overweight due to its stable income and strong financial health. The REIT boasts a 99.1% occupancy rate and 97.5% fixed-rate debt, ensuring steady rental income and protection against interest rate hik...
On September 21, 2026, Sandisk was added to the S&P 100 index, replacing Nike, which was removed on the same day. This change reflects shifts in market capitalization and company performance within the index. The update is significant for investors t...
Several top analysts, including Cantor Fitzgerald, Guggenheim, Morgan Stanley, and BTIG Research, have raised price targets and upgraded their outlooks for ServiceNow, signaling confidence in the company's long-term growth. Despite this, the stock ha...
Nebius Group has been upgraded to a buy rating following a significant improvement in its operating margin, which nearly broke even in the second fiscal quarter after a -32% loss in the first quarter. This turnaround is attributed to capacity expansi...
